Apollo Endosurgery (NASDAQ: APEN) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
This is a breakdown of current ratings and target prices for Apollo Endosurgery and Utah Medical Products, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Utah Medical Products||0||0||0||0||N/A|
Apollo Endosurgery presently has a consensus price target of $11.00, suggesting a potential upside of 67.94%. Given Apollo Endosurgery’s higher possible upside, analysts clearly believe Apollo Endosurgery is more favorable than Utah Medical Products.
Insider & Institutional Ownership
31.3% of Apollo Endosurgery shares are held by institutional investors. Comparatively, 67.1% of Utah Medical Products shares are held by institutional investors. 74.2% of Apollo Endosurgery shares are held by company insiders. Comparatively, 8.8% of Utah Medical Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Apollo Endosurgery has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Earnings & Valuation
This table compares Apollo Endosurgery and Utah Medical Products’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apollo Endosurgery||$64.31 million||1.76||-$27.29 million||($2.15)||-3.05|
|Utah Medical Products||$41.41 million||8.70||$8.50 million||$2.29||42.29|
Utah Medical Products has lower revenue, but higher earnings than Apollo Endosurgery. Apollo Endosurgery is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
This table compares Apollo Endosurgery and Utah Medical Products’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Utah Medical Products||20.54%||18.85%||16.57%|
Utah Medical Products pays an annual dividend of $1.08 per share and has a dividend yield of 1.1%. Apollo Endosurgery does not pay a dividend. Utah Medical Products pays out 47.2% of its earnings in the form of a dividend.
Utah Medical Products beats Apollo Endosurgery on 10 of the 15 factors compared between the two stocks.
About Apollo Endosurgery
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
About Utah Medical Products
Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts. UTMD markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit, the labor and delivery department and the women’s health center in hospitals, as well as products sold to outpatient clinics and physician’s offices.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.